Inducing patent infringement in Hatch-Waxman ANDA litigation

被引：0

|

作者：

Main, Denise

机构：

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2012年 / 244卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

18-CHAL

引用

收藏

页数：1

相关论文

共 50 条

[21] History of the Hatch-Waxman Act.
Leeds, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U396 - U397
[22] Study recommends changes to Hatch-Waxman
不详
PHARMACEUTICAL PATENT ANALYST, 2012, 1 (01) : 20 - 20
[23] Patent term extensions for human drugs under the US Hatch-Waxman Act
Boone, Jeffrey S.
JOURNAL OF INTELLECTUAL PROPERTY LAW & PRACTICE, 2009, 4 (09) : 658 - 664
[24] Toward a Centralized Hatch-Waxman Venue
Makowski, Matthew
UNIVERSITY OF CHICAGO LAW REVIEW, 2022, 89 (07): : 1837 - 1870
[25] Biosimilars: impact of differences with Hatch-Waxman
Kowalchyk, Katherine
Crowley-Weber, Cara
PHARMACEUTICAL PATENT ANALYST, 2013, 2 (01) : 29 - 37
[26] Correcting Hatch-Waxman: An author responds
Birndt, Ernst R.
HEALTH AFFAIRS, 2008, 27 (03) : 903 - 903
[27] 美国Hatch-Waxman法案研究
王鑫
甄橙
东岳论丛, 2017, 38 (01) : 165 - 173
[28] PERSONAL JURISDICTION IN HATCH-WAXMAN CASES
Marusak, Michael
CATHOLIC UNIVERSITY LAW REVIEW, 2016, 66 (01): : 189 - 222
[29] Hatch-Waxman: Where patents meet the FDA
Bohrer, RA
BIOTECHNOLOGY LAW REPORT, 2001, 20 (02) : 165 - 165
[30] Expanding the scope of the Hatch-Waxman Act's patent carve-out exception to the identical drug labeling requirement: Closing the patent litigation loophole
Dohm, Julie
UNIVERSITY OF PENNSYLVANIA LAW REVIEW, 2007, 156 (01) : 151 - 196

← 1 2 3 4 5 →